Interpace Biosciences Inc (IDXG) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Interpace Biosciences Inc stock $15.73, price $6.20, upside +153.7%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Interpace Biosciences Inc
IDXG · USCheap (61% below fair value), solid company and rising price: meets all 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $0.0010 – $7.62 · fair‑value band $11.74 – $24.17 · the $6.20 price screens below the $15.73 fair value. 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 17, 2026.
Every Wednesday you see whether Interpace Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
Show moreShow less
The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals.
The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Stock analysis
Interpace Biosciences Inc (IDXG) currently trades at $6.20, while our model-based Fair Value estimate is $15.73, implying the stock looks roughly 61% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $76.38 per share, and 23 of the 24 models we run sit above the $6.20 price.
Bear case: the Asset-Based group reads lowest at $2.33, and 1 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $11.74 (bear) to $24.17 (bull), the price of $6.20 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Interpace Biosciences Inc reported revenue of $38.7M in FY2025 versus $41.3M in FY2021, a compound −1.6%/yr. Reported net income was $24.6M in FY2025.
Key figures
Market cap $35.7M Micro · P/E ratio 1.4 · P/S ratio 0.87 · EPS (TTM) $4.50 · Net margin 63.5% · Return on equity 226% · Return on assets (EBIT) 8.5% (5-year average) · Operating margin 11.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 66 out of 100 (medium confidence).
What moves the price
The share trades about 19% below its 52-week high and 476,823% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −9% fair-value upside, at 154%, IDXG screens cheaper than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Growth Forecast
Watch IDXG, get fair value alerts →
Compare Interpace Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 151 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Illumina, Inc ILMN | $198.00 | $227.71 | +15% | vs IDXG |
| WuXi AppTec Co 603259 | ¥144.41 | ¥164.66 | +14% | vs IDXG |
| IQVIA Holdings IQV | $264.73 | $291.63 | +10% | vs IDXG |
| Thermo Fisher Scientific Inc TMO | $691.33 | $686.04 | −1% | vs IDXG |
| Danaher Corporation DHR | $229.91 | $209.18 | −9% | vs IDXG |
| IDEXX Laboratories, Inc IDXX | $700.65 | $496.48 | −29% | vs IDXG |
| Lonza Group LONN | CHF 670.20 | CHF 259.80 | −61% | vs IDXG |
| Mettler-Toledo International Inc MTD | $1,727 | $655.06 | −62% | vs IDXG |
| Agilent Technologies, Inc A | $172.92 | $64.20 | −63% | vs IDXG |
| Waters Corporation WAT | $453.42 | $91.26 | −80% | vs IDXG |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Interpace Biosciences Inc (IDXG) overvalued or undervalued?
What is the fair value of IDXG?
What is the quality score of IDXG?
What is the price target for Interpace Biosciences Inc (IDXG)?
What is the Interpace Biosciences Inc stock forecast for 2026?
What is the revenue of Interpace Biosciences Inc (IDXG)?
What growth is priced into Interpace Biosciences Inc (IDXG)?
What discount rate (WACC) does the fair value of IDXG use?
What is a reverse DCF?
How much growth has Interpace Biosciences Inc (IDXG) delivered so far?
How fast is the sector of Interpace Biosciences Inc (IDXG) growing?
What is the free cash flow yield of Interpace Biosciences Inc (IDXG)?
What is the intrinsic value of Interpace Biosciences Inc (IDXG)?
Is Interpace Biosciences Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IDXG?
How much is Interpace Biosciences Inc worth?
What do the bullish and bearish scenarios say about IDXG?
What is the P/E ratio of IDXG?
What is the PEG ratio of IDXG?
How solid is the balance sheet of Interpace Biosciences Inc (IDXG)?
How far is IDXG from its 52-week high?
Which stocks are comparable to Interpace Biosciences Inc?
Is Interpace Biosciences Inc stock attractive at the current price?
How is the fair value of IDXG calculated?
Is it still worth investing in stocks now?
What is the share price of Interpace Biosciences Inc (IDXG)?
What should I pay attention to with Interpace Biosciences Inc right now?
Key figures of Interpace Biosciences Inc
How large is the market capitalisation of Interpace Biosciences Inc (IDXG)?
What is the P/S ratio of Interpace Biosciences Inc (IDXG)?
What are the earnings per share of Interpace Biosciences Inc (IDXG)?
What is the net margin of Interpace Biosciences Inc (IDXG)?
What is the return on equity of Interpace Biosciences Inc (IDXG)?
What is the EBIT return on assets of Interpace Biosciences Inc (IDXG)?
What is the operating margin of Interpace Biosciences Inc (IDXG)?
How fast is revenue growing at Interpace Biosciences Inc (IDXG)?
How fast are earnings growing at Interpace Biosciences Inc (IDXG)?
How much net debt does Interpace Biosciences Inc (IDXG) carry?
Watch Interpace Biosciences Inc in the live analysis
One click puts Interpace Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.